Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2Phase 2 1

Status

Completed 14Terminated 6Recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Breast Neoplasms 1127Neoplasms 982Carcinoma, Non-Small-Cell Lung 900Prostatic Neoplasms 594Neoplasm Metastasis 528Leukemia, Myeloid, Acute 513Colorectal Neoplasms 491Lung Neoplasms 487Melanoma 485Multiple Myeloma 477Pancreatic Neoplasms 385Lymphoma 369Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 346Leukemia 339Leukemia, Lymphocytic, Chronic, B-Cell 321Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 273Carcinoma, Hepatocellular 261Glioblastoma 249Lymphoma, Large B-Cell, Diffuse 244Myelodysplastic Syndromes 242Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

tildrakizumab 1sabizabulin 1enzalutamide 1Pluvicto 1N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × Metastatic Castration Resistant Prostate Cancer × Clear all
NCT03177187 2024-09-26

ACE

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
30 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
13 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT05124795 2024-01-17

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Immunic AG

Phase 1 Terminated
18 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03752099 2023-09-26

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Veru Inc.

Phase 1/2 Terminated
80 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04634344 2022-07-11

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Dizal Pharmaceuticals

Phase 1 Terminated
16 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03042312 2021-03-24

RESIST-PC

Endocyte

Phase 2 Terminated
71 enrolled 15 charts
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡